Pioglitazone Reduces Neointima Volume After Coronary Stent Implantation | Zendy

Nikolaus Marx | Zendy; Jochen Wöhrle | Zendy; Thorsten Nusser | Zendy; Daniel Walcher | Zendy; Angelika Rinker | Zendy; Vinzenz Hombach | Zendy; Wolfgang Köenig | Zendy; Martin Höher | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pioglitazone Reduces Neointima Volume After Coronary Stent Implantation

Author(s) -

Nikolaus Marx,

Jochen Wöhrle,

Thorsten Nusser,

Daniel Walcher,

Angelika Rinker,

Vinzenz Hombach,

Wolfgang Köenig,

Martin Höher

Publication year - 2005

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.105.535484

Subject(s) - medicine , neointima , pioglitazone , restenosis , cardiology , coronary artery disease , stent , coronary stent , placebo , angioplasty , population , coronary atherosclerosis , urology , diabetes mellitus , type 2 diabetes , endocrinology , pathology , alternative medicine , environmental health

Restenosis requiring reintervention limits the long-term success after coronary stent implantation. Thiazolidinediones, like pioglitazone or rosiglitazone, are oral antidiabetic drugs with additional antirestenotic properties. In a randomized, placebo-controlled, double-blind trial, we examined the effect of 6-month pioglitazone therapy on neointima volume after coronary stenting in nondiabetic coronary artery disease patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research